Statistics
Publications
18
Citations
681
H-Index
15
Active since
2013
Michal Sarfaty is an author at Tel Aviv University specializing in medicine, oncology, and cancer immunotherapy.
Publications per year
2013–2023
18
18
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Raz Mutai, Tamar Barkan, Assaf Moore et al. · The Breast · 2021 · 137 citations · Full text
Medicine, Oncology, Breast Oncology +13
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Michal Sarfaty, Moshe Leshno, Noa Gordon et al. · European Urology · 2017 · 67 citations
Assaf Moore, Michal Cohen‐Naftaly, Yulia Kundel et al. · Radiation Oncology · 2017 · 66 citations · Full text
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
Michal Sarfaty, Peter S Hall, Kelvin Chan et al. · European Urology · 2018 · 66 citations · Full text
1–5 of 18